Eli Lilly and Company - Free Cash Flow To Equity

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Free-Cash-Flow-To-Equity" stands at 20.11 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 11.23 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 432.64 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 11.23 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 692.66 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 20.11 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 95.20 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 19.31 Billion United States Dollars compared to the value the year prior.
The 1 year change is 19.31 Billion United States Dollars.
The 3 year change is 14.60 Billion United States Dollars.
The 5 year change is 14.34 Billion United States Dollars.
The 10 year change is 19.05 Billion United States Dollars.

The Serie's long term average value is 4.26 Billion United States Dollars. It's latest available value, on 09/30/2025, is 15.86 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 12/31/2015, to it's latest available value, on 09/30/2025, is +22.51 Billion.
The Serie's change in United States Dollars from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0 Billion.